Activity Description and Educational Objectives

In this activity, an expert in endocrinology discusses the role of SGLT2 inhibitors in managing patients with type 2 diabetes.

Upon completion of this activity, participants should be better able to:

• Describe the rationale for the use of SGLT2 inhibitors in type 2 diabetes
• Integrate SGLT2 inhibitors into clinical practice to reduce CV risk in patients with type 2 diabetes
• Discuss the potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes

Target Audience

This activity has been designed to meet the educational needs of endocrinologists and other clinicians involved in the treatment of patients with type 2 diabetes.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 29, 2018 - June 28, 2019
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Yale School of Medicine
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut

Silvio E. Inzucchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for VTV Therapeutics.
Other Financial or Material Support in the form of clinical trial steering committees for AstraZeneca; Boehringer Ingelheim GmbH; Eisai Inc. (TIMI); Lexicon Pharmaceuticals, Inc./sanofi-aventis U.S. LLC; and Novo Nordisk A/S. In the form of Data Monitoring Board for Intarcia Therapeutics, Inc. Editorial Board Involvement for Practice Update (Diabetes Channel), Journal of Diabetes and Vascular Disease Research, Clinical Diabetes and Endocrinology, Nutrition, Metabolism and Cardiovascular Disease, Endocrine, and Cardiovascular Endocrinology.

Medical Directors

Chris Washburn, PhD
PVI, PeerView Institute for Medical Education

Chris Washburn, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members and reviewers, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Purdue University College of Pharmacy are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Purdue University College of Pharmacy. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions in activities.

Copyright © 2000-2018, PeerView